Mycobacterial Antigen Composition for Latent Infection Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating intracellular mycobacterial infections, such as those caused by Mycobacterium tuberculosis, are hindered by the development of drug-resistant microorganisms and the limited efficacy of existing vaccines, particularly in managing latent infections and preventing reactivation.
Innovation Solution
An antigenic composition comprising a first mycobacterial antigen with at least 70% amino acid sequence identity to latency-regulated polypeptides and a second mycobacterial antigen, designed to induce a robust immune response without antigenic competition, promoting long-term protection against mycobacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat mycobacterial infections, then bacterial growth is inhibited, but drug-resistant microorganisms develop
Solution Approach 1:
The vaccine is divided into multiple components including VAC1 and VAC2 antigens that target different stages of mycobacterial infection (active and latent phases). This segmented approach allows simultaneous targeting of multiple bacterial states without promoting single-point resistance
Solution Approach 2:
The invention uses a composite vaccine formulation combining multiple antigenic components (VAC1, VAC2, and adjuvants) to create a multi-faceted immune response. This composite structure addresses both active and latent infection stages, reducing the likelihood of resistance development
2Reliability
If existing vaccines are administered, then some protection is provided, but they fail to prevent reactivation of latent infections
Solution Approach 1:
The vaccine formulation is designed with multi-functionality to protect against both active and latent mycobacterial infections. The combination of VAC1 and VAC2 antigens provides universal coverage across different infection stages, including prevention of reactivation
Solution Approach 2:
The vaccine induces preemptive immune responses before latent infections can reactivate. By establishing immunity in advance against both active and latent stage antigens, the vaccine prevents reactivation rather than treating it after occurrence
3Adaptability or versatility
If multiple antigens are combined in a vaccine, then broader protection is achieved, but antigenic competition reduces immune response effectiveness
Solution Approach 1:
Adjuvants are used as intermediary substances to enhance and coordinate the immune response to multiple antigens. These adjuvants facilitate simultaneous recognition of VAC1 and VAC2 without antigenic competition, maintaining strong immune responses across all targeted stages
Data Source
AI summary
There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptide.